A randomized, open-label multicentre phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab versus fludarabine cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia.

Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, Shannon M, Flinn IW, Byrd JC Br J Haematol. 2014 Nov,167(4):466-77. doi: 10.1111/bjh.13061. Epub 2014 Aug 8.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, et al. N Engl J Med. 2014 Sep 4,371(10):906-17. doi: 10.1056/NEJMoa1402551.

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses.

Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C. Br J Cancer. 2014 Nov 25,111(11):2051-7. doi: 10.1038/bjc.2014.504. Epub 2014 Sep 30.

Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer – A Phase II Clinical Trial.

Eisterer W, DE Vries A, Ofner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J Anticancer Res. 2014 Nov,34(11):6767-73.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann H, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A, on behalf of the German Hodgkin Study Group, the Swiss Group for Clinical Cancer Research, the Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie und Therapie. Lancet. 2015 Apr 11,385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22.

Pleural decortication of a marginal zone lymphoma.

Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, Neureiter D, Troch M, Greil R, Egle A. Ann Hematol. 2014 Jul,93(7):1253-4. doi: 10.1007/s00277-013-1960-5. Epub 2013 Nov 22.

Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.

Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R, Egle A. Ann Oncol. 2014 Jan,25(1):171-6. doi: 10.1093/annonc/mdt481. Epub 2013 Dec 3.

Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.

Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, Egle A, Greil R. Ann Hematol. 2014 Mar,93(3):459-62. doi: 10.1007/s00277-014-2009-0. Epub 2014 Jan 18.

Human immunodeficiency virus type 2 infections in Austria.

Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, Zangerle R, Egle A, Greil R, Oberkofler H, Eberle J. Wien Klin Wochenschr. 2014 Apr,126(7-8):212-6. doi: 10.1007/s00508-013-0493-1. Epub 2014 Jan 18.

Liver toxicity during temozolomide chemotherapy caused by Chinese herbs.

Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, Moik M, Greil R, Egle A. BMC Complement Altern Med. 2014 Mar 30,14:115. doi: 10.1186/1472-6882-14-115.